Annual Report

Overview

The report describes the company's return to profitability in 2023, with consolidated operating revenue of RMB 2,608,036,951.05. The company invested RMB 581,565,610.75 in R&D, advancing multiple insulin, GLP-1RA, and biosimilar programs. It also expanded international commercialization, obtaining approvals and tenders in emerging markets. Environmental measures included photovoltaic generation of 832,602.51 kWh and reported carbon-dioxide reductions of 502.9 tons.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English, Chinese
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services